41 Biotechnology & Immunology
may contain other proteins and stabilisers (e.g., BSA) which may block reactive groups or reduce labelling effi ciency necessitating buffer exchange or antibody purifi cation prior to conjugation. However, this step is not necessary with kits that are compatible with BSA or other stabilisers in the storage buffer.
It is also important to consider how long you’ll use the antibody conjugate for as the stability of the fi nal product varies from kit to kit. If you’re planning to use the antibody straight away it might not be necessary to use a kit that produces a product that is stable for more than 24 hours.
Conjugation kits are also often designed to react with a predetermined quantity of antibody, which can help researchers to plan experiments if they know how much antibody will be needed. The availability of a certain kit can also help researchers to plan experiments, for example, if they are planning long-term studies, researchers will not only need a highly reproducible conjugated antibody which can be achieved through conjugation kits, but it will also be critical that the kit is available to be repeatedly purchased. Finally, researchers looking into using conjugation kits for their research, should aim to obtain kits from providers offering technical support and useful online tools to help make label decisions easier and more straightforward.
Summary
The antibody conjugation kit market is rapidly growing and is estimated to reach $3.2 billion USD by 2033, growing at a CAGR of 9.2% from 2026 to 2033 [4]. This rapid growth is due in part to the technological advancements in conjugation techniques and rising demand for easy and reliable solutions to expand antibody toolboxes for better immunoassay development. Practically, conjugation kits allow improvements to assay design and performance while expanding experimental capabilities, especially for multiplexing. They also fill critical gaps where prelabelled antibody availability is more limited, such as in veterinary and translational immunology, and in pharma, where researchers need access to scalable and reliable reagents for in-house labelling. With a broad range of conjugation kits now available to meet different workflows and applications, it is now easier than ever to design and conduct high-quality immunoassays across diverse research areas.
References
1. Jax E, et al. Evaluating effects of AIV infection status on ducks using a fl ow cytometry- based differential blood count. Microbiol Spectr. 2023;11(4):e0435122. doi:10.1128/ spectrum.04351-22
2. Lo Giudice A, et al. Establishment of primary cell cultures from canine oral melanomas via fi ne-needle aspiration: a novel tool for tumorigenesis and cancer progression studies. Animals. 2024;14(13):1948.
https://doi.org/10.3390/ani14131948
3. Gawronska-Kozak B, et al. Dermal white adipose tissue (dWAT) is regulated by Foxn1 and Hif-1α during the early phase of skin wound healing. Int J Mol Sci. 2021;23(1):257. doi:10.3390/ijms23010257
4. Verifi ed Market Reports. Global antibody conjugation kits market size by type (direct conjugation kits, indirect conjugation kits), by antibody type (monoclonal antibodies, polyclonal antibodies), by label type (fl uorophores, enzymes), by application (diagnostics, therapeutics), by end user (pharmaceutical companies, biotechnology fi rms), by geographic scope and forecast. March 2025. Available at: https://www. verifi
edmarketreports.com/product/antibody-conjugation-kits-market/ (accessed August 29, 2025)
Author bio: Sharon Sanderson, PhD, is the Product Manager for fl ow reagents and a Flow Cytometry Applications Scientist at Bio-Rad. She obtained her PhD in cancer cell biology from the University of London and spent thirteen years at the University of Oxford conducting research in cancer and immunology fi elds. In 2017, Sharon joined Bio-Rad as an Applications Scientist, before taking up her current position in 2022.
Figure 1: What researchers need to consider when selecting an appropriate conjugation kit.
Read, Share and Comment on this Article, visit:
www.labmate-online.com Characterised compound libraries to accelerate drug discovery
Amsbio provides researchers with access to an extensive portfolio of more than 325,000 fully characterised chemical compounds designed to streamline drug discovery and development. Covering everything from individual inhibitors, agonists, and natural products to ready-to-screen libraries, these high-quality and cost-effective reagents are suited to both academic and industrial applications.
With a focus on areas such as apoptosis, autophagy, cell cycle regulation, immunology, and signalling cascades, the collection includes over 20,000 small molecule inhibitors and agonists offering excellent membrane permeability, high chemical stability, and broad utility in both in vitro and in vivo studies.
Amsbio’s compound libraries, widely adopted by pharmaceutical and biotech high-throughput screening teams, encompass more than 800 curated sets. These include focused bioactive libraries, fragment libraries, natural product libraries, and diversity sets, each designed to probe specific targets or chemical space. All compounds are supplied with stringent quality assurance data - including HNMR, HPLC, and GC profiles - to confirm structural accuracy and purity.
The range also features over 16,000 natural products, such as flavonoids, alkaloids, terpenoids, coumarins, and saponins, supporting research across oncology, infectious disease, neurobiology, and metabolic disorders. In addition, Amsbio offers an expanding collection of PROTAC (Proteolysis Targeting Chimera) molecules. By leveraging the ubiquitin–proteasome system to selectively degrade proteins, PROTACs often demonstrate superior target engagement compared with traditional inhibitors.
Available in a variety of pack sizes to suit different research needs, Amsbio’s comprehensive offering of pre-characterised compounds are readily searchable by CAS number, name, and product code. More information online:
ilmt.co/PL/kox3
65769pr@reply-direct.com
The Spotlight could be on you! Check our Media Information Pack for further details and send your Press Releases to
pr@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
